Translational Advances in Gynecologic Cancers
- 1st Edition - February 13, 2017
- Latest edition
- Editors: Michael Birrer, Lorenzo Ceppi
- Language: English
Translational Advances in Gynecologic Cancers straddles the bench and bed divide by highlighting important and interesting research that is translatable to the clinic. The conte… Read more
Translational Advances in Gynecologic Cancers straddles the bench and bed divide by highlighting important and interesting research that is translatable to the clinic. The contents of this book cover the entire spectrum, from promising laboratory based research, to clinical trial efforts. Further, new therapeutic indications based upon randomized phase III trials are also included.
Clinicians will learn about lab-based science that is about to enter the clinic, along with the rationale behind translational endpoints in trials. Researchers will be able to identify and understand the clinical needs of patients with these types of tumors to improve their research focus.
- Provides a comprehensive description of all evolving translational gynecologic cancer research for clinicians
- Identifies knowledge gaps to inform the next research direction
- Ties together clinical research and patient needs to help both the researcher and clinician
- Addresses genomics, new target therapies, novel tools, and more for ovarian, endometrial, and cervical cancer
Cancer researchers (including fellows, post-docs, technicians, etc.), clinicians (researchers, practitioners, program leaders), and industry partners
Introduction
Part I: Ovarian Cancer
Chapter 1. Origins of Epithelial Ovarian Cancer
- Abstract
- Introduction
- Embryonic Development
- Serous EOC
- Endometrioid EOC
- Mucinous EOC
- Clear Cell Carcinoma
- Concluding Remarks
- References
Chapter 2. Ovarian Cancer Genomics
- Abstract
- Introduction
- Low-Grade Serous Ovarian Cancer
- Clear Cell Ovarian Cancer
- Mucinous Ovarian Cancer
- Advanced Stage Serous Ovarian Cancer
- Generation of Clinically Relevant Signatures in OC
- Gene Expression Signatures for Drug Sensitivity in OC
- Recurrent Ovarian Cancer
- Conclusion
- List of Acronyms and Abbreviations
- References
Chapter 3. Epigenetics
- Abstract
- Introduction
- Epigenetic Changes in Ovarian Cancer
- Expression and Function of Epigenome Modifying Enzymes in OC
- Functional Consequences of Epigenetic Alterations in OC
- Therapeutic Targeting of the OC Epigenome
- Conclusion
- References
Chapter 4. Timing of Cytoreductive Surgery in the Treatment of Advanced Epithelial Ovarian Carcinoma
- Abstract
- Introduction
- History of Ovarian Cancer Surgery: Defining “Optimal”
- The Quest for Complete Gross Resection: a Radical Approach
- Chemotherapy Then and Now: When and How?
- Primary Versus Interval Cytoreduction: Rationale
- Interval Debulking Surgery: a Second Chance
- Neoadjuvant Chemotherapy: Planned from the Start
- Predicting Surgical Success: Translational Advances
- In Conclusion: What Now?
- References
Chapter 5. Angiogenesis
- Abstract
- Introduction
- Angiogenesis
- Vessel Sprouting Model
- Tumor Angiogenesis
- Growth Factor Pathways in Gynecologic Cancers
- Antiangiogenic Therapies in Clinical Trials
- Monoclonal Antibodies
- Receptor Kinase Inhibitors
- Fusion Peptibody
- Combination Biologic Therapy
- Resistance to Antiangiogenic Therapies
- Biomarkers
- Conclusion
- Glossary
- List Of Acronyms and Abbreviations
- References
Chapter 6. Homologous Recombination and BRCA Genes in Ovarian Cancer: Clinical Perspective of Novel Therapeutics
- Abstract
- Introduction
- HR and Double-Strand DNA Break Repair
- HR and Epithelial Ovarian Cancer
- Targeting HRD in Ovarian Cancer
- Promoting HR Deficiency in HR-Proficient Cells
- Conclusion
- References
Chapter 7. Molecular Basis of PARP Inhibition and Future Opportunities in Ovarian Cancer Therapy
- Abstract
- DNA Damage Response
- BRCA Gene Mutations
- BRCA Genotype-Phenotype Associations
- Other Ovarian Cancer Associated Syndromes
- FA-BRCA Pathway
- More Than Just BRCA: Strong Penetrance Genes
- FA-Related Moderate Penetrance Genes
- Low Penetrance Genes
- BRCA Testing for Ovarian Cancer
- Screening and Prophylactic Surgery
- Poly (ADP-Ribose) Polymerase
- PARP Inhibitor Mechanism and Early Clinical Development History
- Clinical Studies of PARP Inhibitors in Ovarian Cancer: Olaparib
- Go-No-Go Decision
- Registration Strategies
- Combination Therapy
- Other PARP Inhibitors
- Predicting Response to PARP Inhibitor Therapy
- Combating Mechanisms of PARP Inhibitor Resistance
- Other Potential Opportunities
- Other DNA Repair Targeted Therapies
- Conclusion
- References
Chapter 8. Ovarian Cancer: New Targets and Future Directions
- Abstract
- Introduction
- Immunotherapy
- Folate Receptor-Targeted Therapy
- Fibroblast Growth Factor Targeting
- PI3K/AKT/mTOR Signaling
- RAS/RAF/MEk/ERK Pathway Inhibition
- p53
- Conclusion
- References
Chapter 9. Novel Chemotherapy Tools: Intraperitoneal Therapy, Dose-Dense Therapy
- Abstract
- Introduction
- Intraperitoneal Therapy
- Dose-Dense Therapy
- Conclusions
- List of Acronyms and Abbreviations
- References
Chapter 10. Updates on Rare Epithelial Ovarian Carcinoma
- Abstract
- Introduction: Epithelial Ovarian Cancer Subtypes
- Low-Grade Serous Carcinoma
- Clear Cell Carcinoma
- Endometrioid Ovarian Carcinoma
- Mucinous Ovarian Carcinoma
- Future Directions
- Conclusions
- References
Part II: Endometrial Cancer
Chapter 11. Endometrial Cancer Genomics
- Abstract
- Introduction
- The Genomics of EECs
- The Genomics of SECs
- The Potential Clinical Utility of Genomic Aberrations in ECs
- The Genomics of UCSs/MMMTs
- Genetic Predisposition to EC
- Conclusion
- Glossary
- List of Acronyms and Abbreviations
- References
Chapter 12. Sentinel Lymph Node Mapping Procedures in Endometrial Cancer
- Abstract
- Introduction
- Sentinel Lymphatic Mapping
- Technique in Endometrial Cancer
- Pathologic Ultrastaging
- Prospective Evaluation
- Incorporation Into an Algorithm
- Conclusion
- References
Chapter 13. The Role of Radiation in Uterine Cancer
- Abstract
- Introduction
- Radiobiology and Radiosensitizers
- Radiation in Early Stage Uterine Cancer
- Locally Advanced Uterine Cancer
- Radiation Delivery Methods
- Medically Inoperable Uterine Cancer
- Conclusion
- List of Acronyms and Abbreviations
- References
Part III: Cervical Cancer
Chapter 14. Novel Therapies for Advanced Cervical Cancer
- Abstract
- Introduction to Cervical Cancer
- The Angiogenesis Story
- Immunotherapeutic Approaches
- Other Promising Therapeutic Strategies
- References
Part IV: Vulvar Cancer
Chapter 15. New Therapies in Vulvar Cancer
- Abstract
- Introduction
- Sentinel Lymph Node Procedure
- Radiotherapy in Vulvar Cancer Patients with a Positive Sentinel Node
- Targeted Therapies
- Conclusion
- Research Agenda
- References
Part V: Fertility and Cancer
Chapter 16. Fertility and Cancer: Fertility Preservation and Fertility Sparing Surgery
- Abstract
- Surgery
- FSS Summary
- Radiation
- Chemotherapy
- Fertility Preservation Efforts and Techniques
- Additional Topics
- References
- Edition: 1
- Latest edition
- Published: February 13, 2017
- Language: English
MB
Michael Birrer
Dr. Michael Birrer is a Professor of Medicine at Harvard Medical School, the Director of Medical Gynecologic Oncology, Gynecologic Oncology Research Program, and the Gellete Center for Gynecologic Oncology at Massachusetts General Hospital (MGH) in Boston, Massachusetts. He is also a practicing physician at MGH.
The Birrer laboratory has had a long-term interest in characterizing the molecular origins of gynecologic cancers. This interest includes the identification and characterization of mutations in oncogenes and tumor suppressor genes within cancers of the ovary, endometrial and cervix. In addition, they have extensively characterized the differential gene expression in these tumors. The role of these genes in the development of these cancers has been tested using in vitro and in vivo model systems. The laboratory is focused on using the genomic events characterized in these cancers to produce translational science endeavors, which will result in clinically important discoveries. These genomic abnormalities form the basis for early detection assays, prevention strategies, and novel therapeutic approaches. Dr. Birrer’s laboratory focuses on bench-to-bedside-and-back-again approaches to produce clinically relevant strategies to better manage women with these cancers.
Affiliations and expertise
Professor, Department of Medicine, Harvard Medical School; Director, Gillette Center for Gynecologic Oncology, Massachusetts General HospitalLC
Lorenzo Ceppi
MD, Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA, USA
Affiliations and expertise
MD, Department of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA, USARead Translational Advances in Gynecologic Cancers on ScienceDirect